LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Suletud

SektorTervishoid

6.16 3.53

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.87

Max

6.25

Põhinäitajad
By Trading Economics
Sissetulek	3M 12M
Müük	21M 76M
P/E Sektori keskmine	9.635 57.833
Kasumimarginaal	15.633
Töötajad	179
EBITDA	13M 27M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-16.67% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-49M 309M
Eelmine avamishind	2.63
Eelmine sulgemishind	6.16

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

3.07 / 3.075 Toetus ja vastupanu

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. märts 2026, 18:34 UTC

Tulu

Canada to Allow Smaller Companies to Ax Quarterly Earnings Reports in Pilot

19. märts 2026, 17:43 UTC

Suurimad hinnamuutused turgudel

Ecolab Dips on Report of Deal for CoolIT Systems With KKR

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings: Geopolitical Tensions Will Continue Driving Regional Fragmentation >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings: Container Shipping Market Saw Fluctuating, Declining Freight Rates >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings 2025 Rev CNY219.50B Vs. CNY233.86B >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings 2025 Net CNY30.86B Vs. Net CNY49.17B >1919.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning 2025 Net CNY2.94B Vs. Net CNY3.01B >2331.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning: Will Continue Targeting Consumer Needs, Strengthening User Engagement >2331.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning: Outdoor Category Continued Growing >2331.HK

19. märts 2026, 23:38 UTC

Tulu

Li Ning 2025 Rev CNY29.60B Vs. CNY28.68B >2331.HK

19. märts 2026, 23:33 UTC

Market Talk

Gold Edges Lower on Inflation Concerns, Dimmed Fed Rate-Cut Hopes -- Market Talk

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Unilever in Talks to Separate Food Business and Combine It With McCormick -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

McCormick Has a Market Value of Around $14.8B -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Unilever in Talks to Combine Food Business With McCormick, Sources Say -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

All-Stock Unilever-McCormick Deal Could Come Together Within Weeks, Sources Say -- WSJ

19. märts 2026, 22:23 UTC

Market Talk

FedEx Says It Can Raise Prices to Offset Higher Fuel Costs -- Market Talk

19. märts 2026, 22:09 UTC

Market Talk

Uudisväärsed sündmused

Australian Transport Stocks to Trade at Discount On Fuel Risks -- Market Talk

19. märts 2026, 22:06 UTC

Market Talk

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

19. märts 2026, 22:04 UTC

Tulu

Omandamised, ülevõtmised, äriostud

FedEx CFO: MD-11 Grounding Led to $120M Headwind to Adjusted Operating Income in 3Q

19. märts 2026, 22:03 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

19. märts 2026, 22:03 UTC

Market Talk

Uudisväärsed sündmused

Fuel Prices, Scarcity Could Leave Mark on Australia's Gold Miners -- Market Talk

19. märts 2026, 21:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

FedEx CEO: InPost Deal Expected to Be Accretive to Earnings in Year One After Close

19. märts 2026, 20:57 UTC

Uudisväärsed sündmused

Middle East Attacks, Inflation Fears Weigh on Stocks -- WSJ

19. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

19. märts 2026, 20:19 UTC

Uudisväärsed sündmused

Brent Crude Retreats After Touching $119 -- WSJ

19. märts 2026, 19:49 UTC

Market Talk

Brent Crude Seen Potentially Rising to Top Its 2008 High -- Market Talk

19. märts 2026, 19:26 UTC

Uudisväärsed sündmused

U.S. Consumers Face 'Global Oil Shock.' The Iran War Is Retail's Latest Challenge. -- Barrons.com

19. märts 2026, 19:10 UTC

Market Talk

Uudisväärsed sündmused

Natural Gas Rises in Volatile Trading -- Market Talk

19. märts 2026, 19:06 UTC

Uudisväärsed sündmused

Brent Crude Prices Are Surging. Why Europe Is Facing an Energy Shock and the U.S. Isn't. -- Barrons.com

19. märts 2026, 18:08 UTC

Market Talk

Uudisväärsed sündmused

Silver Extends Slide to Seven Straight Sessions -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-16.67% langus

12 kuu keskmine prognoos

Keskmine 5 USD -16.67%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.